Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Samarium 153 lexidronam

Next Previous
X
Search
Drug Profile

Samarium 153 lexidronam

Alternative Names: 153SM samarium ethylenediaminetetramethylene phosphonic acid; CYT 424; Quadramet; Samarium 153 EDTMP; Samarium SM 153 lexidronam pentasodium; Sm 153 EDTMP

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dow Chemical
  • Developer CIS bio international; EUSA Pharma; Lantheus Medical Imaging; Superna Life Sciences
  • Class Analgesics; Inorganic chemicals; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Discontinued Bone metastases; Breast cancer; Multiple myeloma; Osteosarcoma; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 02 Apr 2015 Samarium 153 lexidronam is still in phase I/II trials for Multiple myeloma (Combination therapy, Recurrent) in the USA
  • 02 Apr 2015 Samarium 153 lexidronam is still in phase II trials for Prostate cancer in the USA
  • 01 Nov 2014 M.D. Anderson Cancer Center in collaboration with Cytogen complete a phase II trial in Breast Cancer in USA (NCT00429507)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top